Testing effectiveness (Phase 2)Study completedNCT00793572
What this trial is testing
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Who this might be right for
Refractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 32